Lower Extremity Peripheral Arterial Disease and Exercise Ischemia

Intermittent Claudication Clinical Trial

— CLASH  

Official title:

Lower Extremity Peripheral Arterial Disease and Exercise Ischemia: Walking Capacity Variability, Pain Evolution and Pathophysiological Responses. The CLASH Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02041169
• Other study ID #: 35RC13-9907-CLASH
• Secondary ID: 2013-A01381-4413
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Est. completion date: September 2018

Study information

• Verified date: May 2023
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths. In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied. This study is a prospective, cross-sectional study in exercise pathophysiology. The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients. Secondary goals are : 1. To determine the nature of the relationship between the recovery duration and subsequent walking performance. 2. To study the relationship between exercise ischemia, pain evolution and previous recovery duration. 3. To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration. 4. To study the influence of recovery duration on walking capacity from community-based measurement.

Description:

It is expected to determine for the first time an optimal recovery duration that would maximize the walking capacity of LEPAD patients. In the medium term : - To give indications to the LEPAD patients to manage their pain in the community without lower their physical activity. - To limit the functional decline of LEPAD patients. - To influence the quality of life and cardiovascular mortality. This would deserve furthers studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: September 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old
• Insured under the French social security system (according to French law)
• Presence of lower-extremity peripheral artery disease, defined by:
• A resting ankle-brachial index (ABI) = 0.90
• OR if resting ABI > 0.90 and < 1.00, a decrease in recovery ankle systolic pressure or in recovery ABI from treadmill exercise higher than 30% or 20%, respectively (AHA recommendations).
• OR if resting ABI > 1.40, a toe pressure index = 0.70
• Maximal walking distance on treadmill (3.2 km/h, 10% grade) < 500m (a)
• Complain of exertional lower limbs pain that can begin or not at rest, causes the participant to stop walking and relieves or lessens within 10 minutes of rest (assessed using the San Diego questionnaire AND confirmed during treadmill testing) (b)

1. As assessed during the medical appointment.

2. According to our inclusion criteria, patients' leg symptoms that fell within the following leg symptom categories could be included in the study: i) Intermittent claudication. Patients that experience exertional calf pain that does not begin at rest and that forces them to stop walking and that relieves or lessens within 10 minutes of rest; ii) Atypical exertional leg pain/stop. This category can encompass diverse situations of exertional leg symptoms. In the present study, patients in this category were included if they experience exertional pain that does not begin at rest and that forces them to stop walking, but that do not involve only the calf(s) but also thigh(s) and/or buttock(s). Further, the exertional leg pain relieves or lessens within 10 minutes of rest; iii) Leg pain on exertion and rest. In this category, patients sometimes experience exertional leg pain at rest when they are standing still or sitting. On exertion, patients also experience a walking pain as described above. As reminded by Criqui et al., this category of patients with "pain at rest" should not be confused with patients that experience "rest pain", which usually refers to patients with such severe advanced PAD that ischemic pain is present even at rest. Patients with ischemic rest pain were not included in the study. Non-Inclusion criteria

• Exercise limitation due to symptoms not related to an arterial insufficiency in the lower limbs (e.g., dyspnea, angina pectoris)
• Contraindication for walking (Abdominal aortic aneurysm > 4 cm)
• Myocardial infarction and no stroke in the last 3 months
• Critical limb ischemia, amputation.
• Pregnant women
• Adult subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law).
• Patient living more than 50 km from the university hospital
• Patient unable to understand the instructions of the study

Related Conditions & MeSH terms

• Intermittent Claudication
• Ischemia
• Peripheral Arterial Disease
• Peripheral Arterial Diseases
• Peripheral Vascular Diseases

Intervention

Other:
• Subsequent walking performance
Subsequent walking performance

Locations

Country	Name	City	State
France	Rennes University Hospital	Rennes	Brittany

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

References & Publications (4)

Chaudru S, Jehannin P, de Mullenheim PY, Klein H, Jaquinandi V, Mahe G, Le Faucheur A. Using wearable monitors to assess daily walking limitations induced by ischemic pain in peripheral artery disease. Scand J Med Sci Sports. 2019 Nov;29(11):1813-1826. do — View Citation

de Mullenheim PY, Chaudru S, Mahe G, Prioux J, Le Faucheur A. Clinical Interest of Ambulatory Assessment of Physical Activity and Walking Capacity in Peripheral Artery Disease. Scand J Med Sci Sports. 2016 Jul;26(7):716-30. doi: 10.1111/sms.12512. Epub 20 — View Citation

de Mullenheim PY, Rouviere L, Emily M, Chaudru S, Kaladji A, Mahe G, Le Faucheur A. "Should I stay or should I go now?" Recovery time effect on walking capacity in symptomatic peripheral artery disease. J Appl Physiol (1985). 2021 Jul 1;131(1):207-219. do — View Citation

Donnou C, Chaudru S, Stivalet O, Paul E, Charasson M, Selli JM, Mauger C, Chapron A, Le Faucheur A, Jaquinandi V, Mahe G. How to become proficient in performance of the resting ankle-brachial index: Results of the first randomized controlled trial. Vasc M — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking	Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking	32 days
Other	Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements.	Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements	32 days
Primary	Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses.	Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses.	32 days
Secondary	Coefficient of determination determined from different curves fitting	Coefficient of determination determined from different curves fitting	32 days